MX2015012613A - Composicion para administracion oral para enlazar aldheidos en el tracto gastrointestinal. - Google Patents
Composicion para administracion oral para enlazar aldheidos en el tracto gastrointestinal.Info
- Publication number
- MX2015012613A MX2015012613A MX2015012613A MX2015012613A MX2015012613A MX 2015012613 A MX2015012613 A MX 2015012613A MX 2015012613 A MX2015012613 A MX 2015012613A MX 2015012613 A MX2015012613 A MX 2015012613A MX 2015012613 A MX2015012613 A MX 2015012613A
- Authority
- MX
- Mexico
- Prior art keywords
- cysteine
- composition
- aldehydes
- oral administration
- gastrointestinal tract
- Prior art date
Links
- 150000001299 aldehydes Chemical class 0.000 title abstract 3
- 210000001035 gastrointestinal tract Anatomy 0.000 title 1
- 239000000654 additive Substances 0.000 abstract 2
- 210000001072 colon Anatomy 0.000 abstract 2
- 150000001945 cysteines Chemical class 0.000 abstract 2
- 210000000813 small intestine Anatomy 0.000 abstract 2
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 abstract 1
- 229930195710 D‐cysteine Natural products 0.000 abstract 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 229960004308 acetylcysteine Drugs 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 201000000498 stomach carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición no tóxica que contiene uno o más compuestos de cisteína seleccionados entre L- o D-cisteína, N-acetilcisteína, y sus sales farmacéuticamente aceptables, para reducir el riesgo de que un sujeto contraiga cáncer de estómago, intestino delgado y colon, al enlazar localmente los aldehídos presentes en el estómago, y opcionalmente separar los aldehídos llevados al intestino delgado o colon, o ambos, por lo que la composición se formula con la ayuda de dos o más aditivos en tabletas de liberación controlada conteniendo al menos un aditivo seleccionado de polímeros catiónicos y formadores de gel, tales tabletas se forman de dos o más capas separadas con diferentes perfiles de liberación, por lo que los compuestos de cisteína se agregan tanto en la capa(s) interna como al material de tableta que la rodea.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/FI2013/050274 WO2014140410A1 (en) | 2013-03-12 | 2013-03-12 | Composition for oral administration for binding aldehydes in the gastrointestinal tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015012613A true MX2015012613A (es) | 2016-07-06 |
Family
ID=48044818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012613A MX2015012613A (es) | 2013-03-12 | 2013-03-12 | Composicion para administracion oral para enlazar aldheidos en el tracto gastrointestinal. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160022621A1 (es) |
| JP (1) | JP2016514120A (es) |
| KR (1) | KR20150126383A (es) |
| CA (1) | CA2905236A1 (es) |
| IL (1) | IL241450A0 (es) |
| MX (1) | MX2015012613A (es) |
| WO (1) | WO2014140410A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113018271B (zh) * | 2019-12-25 | 2022-08-09 | 四川科瑞德制药股份有限公司 | 一种坦度螺酮药物组合物及其制备方法和用途 |
| US11231278B1 (en) | 2020-10-15 | 2022-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | System and method for generating broadband spectrum by phase modulation of multiple wavelengths |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4496548A (en) | 1983-02-04 | 1985-01-29 | Moldowan Mervin J | Composition and method for reducing hangover |
| US4528295A (en) | 1983-08-15 | 1985-07-09 | Boris Tabakoff | Composition and method for reducing blood acetaldehyde levels |
| US5202354A (en) | 1986-02-18 | 1993-04-13 | Takeda Chemical Industries, Ltd. | Composition and method for reducing acetaldehyde toxicity |
| US5906811A (en) | 1997-06-27 | 1999-05-25 | Thione International, Inc. | Intra-oral antioxidant preparations |
| US5922346A (en) | 1997-12-01 | 1999-07-13 | Thione International, Inc. | Antioxidant preparation |
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| FI121528B (fi) | 2000-10-30 | 2010-12-31 | Biohit Oyj | Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa |
| JP5654726B2 (ja) | 2004-10-08 | 2015-01-14 | ビオヒット・ユルキネン・オサケユキテュアＢｉｏｈｉｔ Ｏｙｊ | 唾液中のアルデヒド類を結合するための方法および製剤 |
| US20090196889A1 (en) * | 2004-11-22 | 2009-08-06 | Dexcel Pharma Technologies Ltd. | Controlled absorption of statins in the intestine |
| FI20060501L (fi) * | 2006-05-22 | 2007-11-23 | Biohit Oyj | Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa |
| FI20115377A (fi) * | 2011-04-18 | 2012-10-19 | Biohit Oyj | Ylempien hengitys- ja ruoansulatuselinten mikrobi-infektioihin liittyvissä tiloissa käytettäväksi tarkoitettuja lääketieteellisiä tuotteita |
-
2013
- 2013-03-12 CA CA2905236A patent/CA2905236A1/en not_active Abandoned
- 2013-03-12 JP JP2015562271A patent/JP2016514120A/ja not_active Withdrawn
- 2013-03-12 MX MX2015012613A patent/MX2015012613A/es unknown
- 2013-03-12 WO PCT/FI2013/050274 patent/WO2014140410A1/en active Application Filing
- 2013-03-12 KR KR1020157027063A patent/KR20150126383A/ko not_active Application Discontinuation
- 2013-03-12 US US14/774,875 patent/US20160022621A1/en not_active Abandoned
-
2015
- 2015-09-10 IL IL241450A patent/IL241450A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150126383A (ko) | 2015-11-11 |
| US20160022621A1 (en) | 2016-01-28 |
| JP2016514120A (ja) | 2016-05-19 |
| WO2014140410A1 (en) | 2014-09-18 |
| CA2905236A1 (en) | 2014-09-18 |
| IL241450A0 (en) | 2015-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
| CY1120939T1 (el) | Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου | |
| JP2015536964A5 (es) | ||
| EA201690107A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| CY1115959T1 (el) | 2-αμινοβενζιμιδαζολο-5-καρβοξαμιδιο ως αντι-φλεγμονωδεις παραγοντες | |
| CY1116645T1 (el) | Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch | |
| RU2015121367A (ru) | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний | |
| TR201819653T4 (tr) | Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik. | |
| MD4684B1 (ro) | Formulări pe bază de imidazopirazine în calitate de inhibitori SYK | |
| TN2012000392A1 (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| JP2017526662A5 (es) | ||
| WO2016127168A3 (en) | Mebendazole polymorph for treatment and prevention of tumors | |
| PL3793534T3 (pl) | Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego | |
| EP2588106A4 (en) | DELAYED RELEASED PHARMACEUTICAL COMPOSITION WITH PRAMIPEXOL OR A PHARMACEUTICALLY ALLOWED SALT AND INCREASED STABILITY | |
| EP2950809A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE ORAL TREATMENT OF DIABETES | |
| WO2014201016A3 (en) | Inhibitors of the mitf molecular pathway | |
| JO3256B1 (ar) | صياغات من مركبات عضوية | |
| FI3042669T3 (fi) | Antituumoriaine ja antituumorivaikutuksen tehostaja | |
| MX2015012613A (es) | Composicion para administracion oral para enlazar aldheidos en el tracto gastrointestinal. | |
| NZ719000A (en) | Slow-release solid oral compositions | |
| WO2015060907A3 (en) | Medical bite blocks or mouthpieces | |
| JP2014509637A5 (es) | ||
| MX2015015681A (es) | Composicion farmaceutica que comprende fingolimod. | |
| EP3735238A4 (en) | STABLE ORAL PHARMACEUTICAL COMPOSITION OF IRON CITRATE | |
| TW201613580A (en) | Ceritinib formulation |